Literature DB >> 22228966

Multi-modality treatment of colorectal liver metastases.

Guo-Xiang Cai1, San-Jun Cai.   

Abstract

Liver metastases synchronously or metachronously occur in approximately 50% of colorectal cancer patients. Multimodality comprehensive treatment is the best therapeutic strategy for these patients. However, the optimal pattern of multimodality therapy is still controversial, and it raises several significant concerns. Liver resection is the most important treatment for colorectal liver metastases. The definition of resectability has shifted to focus on the completion of R0 resection and normal liver function maintenance. The role of neoadjuvant and adjuvant chemotherapy still needs to be clarified. The management of either progression or complete remission during neoadjuvant chemotherapy is challenging. The optimal sequencing of surgery and chemotherapy in synchronous colorectal liver metastases patients is still unclear. Conversional chemotherapy, portal vein embolization, two-stage resection, and tumor ablation are effective approaches to improve resectability for initially unresectable patients. Several technical issues and concerns related to these methods need to be further explored. For patients with definitely unresectable liver disease, the necessity of resecting the primary tumor is still debatable, and evaluating and predicting the efficacy of targeted therapy deserve further investigation. This review discusses different patterns and important concerns of multidisciplinary treatment of colorectal liver metastases.

Entities:  

Keywords:  Colorectal cancer; Liver metastases; Multimodality therapy

Mesh:

Year:  2012        PMID: 22228966      PMCID: PMC3251801          DOI: 10.3748/wjg.v18.i1.16

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  91 in total

1.  THE RATIONALE OF PALLIATIVE RESECTION FOR PRIMARY CANCER OF THE COLON AND RECTUM COMPLICATED BY LIVER AND LUNG METASTASIS.

Authors:  H E BACON; P V MARTIN
Journal:  Dis Colon Rectum       Date:  1964 May-Jun       Impact factor: 4.585

2.  Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: an analysis of surveillance, epidemiology, and end results data, 1988 to 2000.

Authors:  Alan D Cook; Richard Single; Laurence E McCahill
Journal:  Ann Surg Oncol       Date:  2005-06-20       Impact factor: 5.344

3.  Treatment efficacy of radiofrequency ablation of 338 patients with hepatic malignant tumor and the relevant complications.

Authors:  Min-Hua Chen; Wei Yang; Kun Yan; Wen Gao; Ying Dai; Yan-Bin Wang; Xiao-Peng Zhang; Shan-Shan Yin
Journal:  World J Gastroenterol       Date:  2005-10-28       Impact factor: 5.742

4.  Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.

Authors:  Y Fong; J Fortner; R L Sun; M F Brennan; L H Blumgart
Journal:  Ann Surg       Date:  1999-09       Impact factor: 12.969

5.  Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases.

Authors:  Timothy M Pawlik; Charles R Scoggins; Daria Zorzi; Eddie K Abdalla; Axel Andres; Cathy Eng; Steven A Curley; Evelyne M Loyer; Andrea Muratore; Gilles Mentha; Lorenzo Capussotti; Jean-Nicolas Vauthey
Journal:  Ann Surg       Date:  2005-05       Impact factor: 12.969

6.  Radiofrequency-ablation of unresectable primary and secondary liver tumors: results in 88 patients.

Authors:  Philipp Hildebrand; Markus Kleemann; Uwe J Roblick; Lutz Mirow; Matthias Birth; Thorsten Leibecke; Hans-Peter Bruch
Journal:  Langenbecks Arch Surg       Date:  2006-03-25       Impact factor: 3.445

7.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

8.  Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?

Authors:  René Adam; Gerard Pascal; Denis Castaing; Daniel Azoulay; Valerie Delvart; Bernard Paule; Francis Levi; Henri Bismuth
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

9.  Factors influencing the local failure rate of radiofrequency ablation of colorectal liver metastases.

Authors:  Fredericke H van Duijnhoven; Maarten C Jansen; Jan M C Junggeburt; Richard van Hillegersberg; Arjen M Rijken; Frits van Coevorden; Joost R van der Sijp; Thomas M van Gulik; Gerrit D Slooter; Joost M Klaase; Hein Putter; Rob A E M Tollenaar
Journal:  Ann Surg Oncol       Date:  2006-03-17       Impact factor: 5.344

10.  Radiofrequency thermal ablation of liver carcinoma. Prospective study of 82 lesions.

Authors:  Emilie Lermite; Jérôme Lebigot; Frédéric Oberti; Patrick Pessaux; Christophe Aube; Paul Cales; Jean-Pierre Arnaud
Journal:  Gastroenterol Clin Biol       Date:  2006-01
View more
  8 in total

1.  Posthepatectomy liver failure after simultaneous versus staged resection of colorectal cancer and synchronous hepatic metastases.

Authors:  D Patrono; G Paraluppi; M Perino; M Palisi; G Migliaretti; P Berchialla; R Romagnoli; M Salizzoni
Journal:  G Chir       Date:  2014 Mar-Apr

Review 2.  Transarterial chemoembolization (TACE) for colorectal liver metastases--current status and critical review.

Authors:  Alexander Massmann; Thomas Rodt; Steffen Marquardt; Roland Seidel; Katrina Thomas; Frank Wacker; Götz M Richter; Hans U Kauczor; Arno Bücker; Philippe L Pereira; Christof M Sommer
Journal:  Langenbecks Arch Surg       Date:  2015-06-19       Impact factor: 3.445

3.  Robot-assisted one-stage resection of rectal cancer with liver and lung metastases.

Authors:  Jian-Min Xu; Ye Wei; Xiao-Ying Wang; Hong Fan; Wen-Ju Chang; Li Ren; Wei Jiang; Jia Fan; Xin-Yu Qin
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

4.  Efficacy of ex vivo activated and expanded natural killer cells and T lymphocytes for colorectal cancer patients.

Authors:  Baskar Subramani; Chithra Ramanathan Pullai; Kohila Krishnan; Sheela Devi Sugadan; Xuewen Deng; Terunuma Hiroshi; Kananathan Ratnavelu
Journal:  Biomed Rep       Date:  2014-03-26

Review 5.  Liver resection in selected patients with metastatic breast cancer: a single-centre analysis and review of literature.

Authors:  Y Dittmar; A Altendorf-Hofmann; S Schüle; M Ardelt; O Dirsch; I B Runnebaum; U Settmacher
Journal:  J Cancer Res Clin Oncol       Date:  2013-05-04       Impact factor: 4.553

6.  CDX2 inhibits epithelial-mesenchymal transition in colorectal cancer by modulation of Snail expression and β-catenin stabilisation via transactivation of PTEN expression.

Authors:  Junhui Yu; Shan Li; Zhengshui Xu; Jing Guo; Xiaopeng Li; Yunhua Wu; Jianbao Zheng; Xuejun Sun
Journal:  Br J Cancer       Date:  2020-11-26       Impact factor: 7.640

7.  Short-course neoadjuvant chemoradiotherapy and surgery are beneficial in Chinese patients: A retrospective study.

Authors:  Ming Jun Huang; Xiao Dong Wang; Yan Jie Hu; Jie Yang; Ka Li
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

8.  Effect of Chinese Herbal Medicine on the Survival of Colorectal Cancer Patients With Liver-Limited Metastases: A Retrospective Cohort Study, 2008 to 2017.

Authors:  Cui Shao; Qian Zuo; Jietao Lin; Rong Jian Yu; Yuanfeng Fu; Min Xiao; Ling Ling Sun; Lizhu Lin
Journal:  Integr Cancer Ther       Date:  2019 Jan-Dec       Impact factor: 3.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.